Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.

@article{Kim2004VasopressinAD,
  title={Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.},
  author={Roy Kim and Clara Malattia and Michaela Allen and Thomas Moshang and Mohamad Maghnie},
  journal={Pediatric endocrinology reviews : PER},
  year={2004},
  volume={2 Suppl 1},
  pages={
          115-23
        }
}
The management of central diabetes insipidus has been greatly simplified by the introduction of desmopressin (DDAVP). Its ease of administration, safety and tolerability make DDAVP the first line agent for outpatient treatment of central diabetes insipidus. The major complication of DDAVP therapy is water intoxication and hyponatremia. The risk of hyponatremia can be reduced by careful dose titration when initiating therapy and by close monitoring of serum osmolality when DDAVP is used with… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Similar Papers

Loading similar papers…